StreetInsider.com News Articles

Metagenomi Inc (MGX) PT Lowered to $7 at Wells Fargo

Tue, 11 Aug 2026 06:56:35 -0400

Wells Fargo analyst Yanan Zhu lowered the price target on Metagenomi Inc (NASDAQ: MGX) to $7.00 (from $9.00) while maintaining a Overweight rating.

The analyst comments "MGX-001 remains on track for an IND submission in 4Q26, with IND-enabling studies, including GLP toxicology, expected to be completed this quarter. 2Q26 earnings results. Net loss per share was ($0.73) vs. consensus of ($0.55). The miss was primarily driven by a $2.6MM non-cash Ionis collaboration adjustment and higher- than-expected R&D expense. MGX ended the quarter with a cash position of $121MM, which is expected to fund operations through 4Q27 (consistent with prior guidance). Our

Metagenomi Inc (MGX) PT Lowered to $7 at Wells Fargo

Tue, 11 Aug 2026 06:56:35 -0400

Wells Fargo analyst Yanan Zhu lowered the price target on Metagenomi Inc (NASDAQ: MGX) to $7.00 (from $9.00) while maintaining a Overweight rating.

Metagenomi, Inc. (MGX) Tops Q2 EPS by 5c

Mon, 10 Aug 2026 18:23:12 -0400

Metagenomi, Inc. (NASDAQ: MGX) reported Q2 EPS of ($0.73), $0.05 better than the analyst estimate of ($0.78).

For earnings history and earnings-related data on Metagenomi, Inc. (MGX) click here.

Form 10-Q Metagenomi Therapeutics, For: Jun 30

Mon, 10 Aug 2026 16:13:00 -0400

si-local-file:///var/storage/secattach/20260810/26898035.html

Form 10-Q Metagenomi Therapeutics, For: Jun 30

Mon, 10 Aug 2026 16:13:00 -0400

si-local-file:///var/storage/secattach/20260810/26898035.html

Form 8-K Metagenomi Therapeutics, For: Aug 10

Mon, 10 Aug 2026 16:11:00 -0400

si-local-file:///var/storage/secattach/20260810/26897970.html

Form 8-K Metagenomi Therapeutics, For: Aug 10

Mon, 10 Aug 2026 16:11:00 -0400

si-local-file:///var/storage/secattach/20260810/26897970.html

Metagenomi Therapeutics Reports Business Updates and Second Quarter 2026 Financial Results

Mon, 10 Aug 2026 16:05:00 -0400

Remains on track to submit investigational new drug (IND) application in 4Q 2026 for the global clinical program of MGX-001 for the treatment of hemophilia A

$120.7 million in cash, cash equivalents, and available-for-sale marketable securities as of June 30, 2026, with runway anticipated to support operations through 4Q 2027

EMERYVILLE, Calif., Aug. 10, 2026 (GLOBE NEWSWIRE) -- Metagenomi Therapeutics, Inc. (Nasdaq: MGX) (the “Company”), an in vivo genome editing company capitalizing on its proprietary technologies to create curative genetic medicines for patients, today reported financial results for the second quarter ended June

Metagenomi Therapeutics Reports Business Updates and Second Quarter 2026 Financial Results

Mon, 10 Aug 2026 16:05:00 -0400

Remains on track to submit investigational new drug (IND) application in 4Q 2026 for the global clinical program of MGX-001 for the treatment of hemophilia A

$120.7 million in cash, cash equivalents, and available-for-sale marketable securities as of June 30, 2026, with runway anticipated to support operations through 4Q 2027

Prolynx names CFO and CSO to advance obesity drug portfolio

Wed, 15 Jul 2026 08:01:18 -0400

Prolynx, a biotechnology company developing ultra-long-acting medicines for obesity and metabolic diseases, has appointed Simon Harnest as Chief Financial Officer and Amer Mirza, PhD, as Chief Scientific Officer, according to a company statement.

Harnest brings experience in life sciences finance, including involvement in three Nasdaq IPOs and more than $1 billion in capital raised. He most recently served as CFO of Totus Medicines and previously held senior roles at Metagenomi (Nasdaq: MGX) and Cellectis (Nasdaq: CLLS).

"Prolynx is building in one of the most important and dynamic areas of medicine, in a field still largely defined by weekly injectable therapies," Harnest said.

Prolynx names CFO and CSO to advance obesity drug portfolio

Wed, 15 Jul 2026 08:01:18 -0400

"Prolynx is building in one of the most important and dynamic areas of medicine, in a field still largely defined by weekly injectable therapies," Harnest said.

Prolynx names CFO and CSO to advance obesity drug portfolio

Wed, 15 Jul 2026 08:01:18 -0400

"Prolynx is building in one of the most important and dynamic areas of medicine, in a field still largely defined by weekly injectable therapies," Harnest said.

Prolynx names CFO and CSO to advance obesity drug portfolio

Wed, 15 Jul 2026 08:01:18 -0400

"Prolynx is building in one of the most important and dynamic areas of medicine, in a field still largely defined by weekly injectable therapies," Harnest said.

Prolynx names CFO and CSO to advance obesity drug portfolio

Wed, 15 Jul 2026 08:01:18 -0400

"Prolynx is building in one of the most important and dynamic areas of medicine, in a field still largely defined by weekly injectable therapies," Harnest said.

Prolynx names CFO and CSO to advance obesity drug portfolio

Wed, 15 Jul 2026 08:01:18 -0400

"Prolynx is building in one of the most important and dynamic areas of medicine, in a field still largely defined by weekly injectable therapies," Harnest said.

Prolynx names CFO and CSO to advance obesity drug portfolio

Wed, 15 Jul 2026 08:01:18 -0400

"Prolynx is building in one of the most important and dynamic areas of medicine, in a field still largely defined by weekly injectable therapies," Harnest said.

Prolynx Names Simon Harnest as Chief Financial Officer and Amer Mirza, PhD, as Chief Scientific Officer as It Advances Multi-Program Obesity and Metabolic Disease Portfolio

Wed, 15 Jul 2026 08:00:00 -0400

EMERYVILLE, Calif., July 15, 2026 (GLOBE NEWSWIRE) -- Prolynx, a biotechnology company developing a next-generation portfolio of ultra-long-acting medicines for obesity and related metabolic conditions, today announced two additions to its executive leadership team: Simon Harnest as Chief Financial Officer and Amer Mirza, PhD, as Chief Scientific Officer. The appointments deepen the company’s leadership bench as Prolynx advances multiple ultra-long-acting candidates for obesity and related metabolic diseases toward IND-enabling studies.